The promise and peril of engineering biology, w/Ginkgo Bioworks Reshma Shetty

Masters of Scale: Rapid Response

תוכן מסופק על ידי WaitWhat. כל תוכן הפודקאסטים כולל פרקים, גרפיקה ותיאורי פודקאסטים מועלים ומסופקים ישירות על ידי WaitWhat או שותף פלטפורמת הפודקאסט שלו. אם אתה מאמין שמישהו משתמש ביצירה שלך המוגנת בזכויות יוצרים ללא רשותך, אתה יכול לעקוב אחר התהליך המתואר כאן https://he.player.fm/legal.

3y ago 27:14

MP3•בית הפרקים

סדרה בארכיון ("עדכון לא פעיל" status)

When? This feed was archived on July 02, 2022 07:22 (2y ago). Last successful fetch was on May 26, 2022 09:33 (2y ago)

Why? עדכון לא פעיל status. השרתים שלנו לא הצליחו לאחזר פודקאסט חוקי לזמן ממושך.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Moderna's Covid-19 vaccine would not have scaled without Ginkgo Bioworks. Reshma Shetty, co-founder and COO of Ginkgo – slated to go public via SPAC acquisition at a reported $15 billion valuation – explains how biotech innovation can build a better future now. Ginkgo's platform already serves industries from food and agriculture, to materials, to healthcare. Shetty acknowledges that engineering genes is a high stakes pursuit, and says Ginkgo is trying to pair the ambition of Silicon Valley with a "higher level of care" than consumer tech companies like social media have demonstrated. The key, Shetty says, is creating an unstable equilibrium – propelling progress but not at the expense of principles.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

120 פרקים

#MBA #Business #WaitWhat #Entrepreneurship #Entrepreneur #Startup #Technology #On Covid19 #Pandemic